These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30344925)

  • 1. Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models.
    Quanz M; Hagemann UB; Zitzmann-Kolbe S; Stelte-Ludwig B; Golfier S; Elbi C; Mumberg D; Ziegelbauer K; Schatz CA
    Oncotarget; 2018 Sep; 9(75):34103-34121. PubMed ID: 30344925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
    Santin AD; Vergote I; González-Martín A; Moore K; Oaknin A; Romero I; Diab S; Copeland LJ; Monk BJ; Coleman RL; Herzog TJ; Siegel J; Kasten L; Schlicker A; Schulz A; Köchert K; Walter AO; Childs BH; Elbi C; Bulat I
    Int J Gynecol Cancer; 2023 Apr; 33(4):562-570. PubMed ID: 36564099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
    Hassan R; Blumenschein GR; Moore KN; Santin AD; Kindler HL; Nemunaitis JJ; Seward SM; Thomas A; Kim SK; Rajagopalan P; Walter AO; Laurent D; Childs BH; Sarapa N; Elbi C; Bendell JC
    J Clin Oncol; 2020 Jun; 38(16):1824-1835. PubMed ID: 32213105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.
    Kindler HL; Novello S; Bearz A; Ceresoli GL; Aerts JGJV; Spicer J; Taylor P; Nackaerts K; Greystoke A; Jennens R; Calabrò L; Burgers JA; Santoro A; Cedrés S; Serwatowski P; Ponce S; Van Meerbeeck JP; Nowak AK; Blumenschein G; Siegel JM; Kasten L; Köchert K; Walter AO; Childs BH; Elbi C; Hassan R; Fennell DA
    Lancet Oncol; 2022 Apr; 23(4):540-552. PubMed ID: 35358455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.
    Golfier S; Kopitz C; Kahnert A; Heisler I; Schatz CA; Stelte-Ludwig B; Mayer-Bartschmid A; Unterschemmann K; Bruder S; Linden L; Harrenga A; Hauff P; Scholle FD; Müller-Tiemann B; Kreft B; Ziegelbauer K
    Mol Cancer Ther; 2014 Jun; 13(6):1537-48. PubMed ID: 24714131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favorable therapeutic response after anti-Mesothelin antibody-drug conjugate treatment requires high expression of Mesothelin in tumor cells.
    Lazzerini L; Jöhrens K; Sehouli J; Cichon G
    Arch Gynecol Obstet; 2020 Nov; 302(5):1255-1262. PubMed ID: 32815024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine.
    Chen V; Umemura S; Han Y; Raman R; Tucker R; Chahine J; Kim IK; Schatz C; Zitzmann-Kolbe S; Sommer A; Onda M; Lee T; He Y; Giaccone G
    Br J Cancer; 2022 Mar; 126(5):754-763. PubMed ID: 34876673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma.
    Mansfield AS; Vivien Yin J; Bradbury P; Kwiatkowski DJ; Patel S; Bazhenova LA; Forde P; Lou Y; Dizona P; Villaruz LC; Arnold SM; Khalil M; Kindler HL; Koczywas M; Pacheco J; Rolfo C; Xia B; Mikula E; Chen L; Patel K; Smith KER; Cao L; Shapiro G; Costello BA; Adjei A; Sharon E; Moscow JA; Zamboni W; Hassan R
    Lung Cancer; 2024 Sep; 195():107928. PubMed ID: 39197359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesothelin as a target for cervical cancer therapy.
    Jöhrens K; Lazzerini L; Barinoff J; Sehouli J; Cichon G
    Arch Gynecol Obstet; 2019 Jan; 299(1):211-216. PubMed ID: 30324544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel mesothelin antibody-drug conjugates: current evidence and future role in the treatment of ovarian cancer.
    Mauricio D; Harold J; Tymon-Rosario JR; Zeybek B; Santin AD
    Expert Opin Biol Ther; 2021 Aug; 21(8):1087-1096. PubMed ID: 33356644
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeting mesothelin in ovarian cancer.
    Ghafoor A; Thomas A; Hassan R
    Oncotarget; 2018 Nov; 9(90):36050-36051. PubMed ID: 30546824
    [No Abstract]   [Full Text] [Related]  

  • 12. Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
    Hassan R; Thomas A; Alewine C; Le DT; Jaffee EM; Pastan I
    J Clin Oncol; 2016 Dec; 34(34):4171-4179. PubMed ID: 27863199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors.
    Zhao XY; Subramanyam B; Sarapa N; Golfier S; Dinter H
    Clin Cancer Drugs; 2016 Oct; 3(2):76-86. PubMed ID: 27853672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies.
    Zitzmann-Kolbe S; Kristian A; Zopf D; Kamfenkel C; Politz O; Ellingsen C; Hilbig J; Juul MU; Fonslet J; Nielsen CH; Schatz CA; Bjerke RM; Cuthbertson AS; Mumberg D; Hagemann UB
    Mol Cancer Ther; 2023 Sep; 22(9):1073-1086. PubMed ID: 37365121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Systemic Treatment of Malignant Pleural Mesothelioma].
    Nakano T
    Gan To Kagaku Ryoho; 2017 Dec; 44(13):2041-2047. PubMed ID: 29361614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
    Ponte JF; Ab O; Lanieri L; Lee J; Coccia J; Bartle LM; Themeles M; Zhou Y; Pinkas J; Ruiz-Soto R
    Neoplasia; 2016 Dec; 18(12):775-784. PubMed ID: 27889646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models.
    Schönfeld K; Herbener P; Zuber C; Häder T; Bernöster K; Uherek C; Schüttrumpf J
    Pharm Res; 2018 Apr; 35(6):118. PubMed ID: 29666962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic Effect of a Mesothelin-Targeted
    Wickstroem K; Hagemann UB; Cruciani V; Wengner AM; Kristian A; Ellingsen C; Siemeister G; Bjerke RM; Karlsson J; Ryan OB; Linden L; Mumberg D; Ziegelbauer K; Cuthbertson AS
    J Nucl Med; 2019 Sep; 60(9):1293-1300. PubMed ID: 30850485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer.
    Klinghammer K; Politz O; Eder T; Otto R; Raguse JD; Albers A; Kaufmann A; Tinhofer I; Hoffmann J; Keller U; Keilholz U
    Oncotarget; 2020 Oct; 11(41):3688-3697. PubMed ID: 33110476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesothelin expression in esophageal adenocarcinoma and squamous cell carcinoma and its possible impact on future treatment strategies.
    Moentenich V; Comut E; Gebauer F; Tuchscherer A; Bruns C; Schroeder W; Buettner R; Alakus H; Loeser H; Zander T; Quaas A
    Ther Adv Med Oncol; 2020; 12():1758835920917571. PubMed ID: 32547645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.